Cluster for Pioneering Research, RIKEN.
A. Butlerov Institute of Chemistry, Kazan Federal University.
Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(3):79-94. doi: 10.2183/pjab.96.007.
In order to harness the functionality of metals, nature has evolved over billions of years to utilize metalloproteins as key components in numerous cellular processes. Despite this, transition metals such as ruthenium, palladium, iridium, and gold are largely absent from naturally occurring metalloproteins, likely due to their scarcity as precious metals. To mimic the evolutionary process of nature, the field of artificial metalloenzymes (ArMs) was born as a way to benefit from the unique chemoselectivity and orthogonality of transition metals in a biological setting. In its current state, numerous examples have successfully incorporated transition metals into a variety of protein scaffolds. Using these ArMs, many examples of new-to-nature reactions have been carried out, some of which have shown substantial biocompatibility. Given the rapid rate at which this field is growing, this review aims to highlight some important studies that have begun to take the next step within this field; namely the development of ArM-centered drug therapies or biotechnological tools.
为了利用金属的功能,自然界经过数十亿年的进化,利用金属蛋白作为许多细胞过程中的关键成分。尽管如此,像钌、钯、铱和金这样的过渡金属在天然存在的金属蛋白中却很少见,这可能是因为它们作为贵金属很稀缺。为了模拟自然界的进化过程,人工金属酶(ArMs)领域应运而生,它可以利用过渡金属在生物环境中的独特化学选择性和正交性从中受益。在目前的状态下,已经有许多成功的例子将过渡金属纳入到各种蛋白质支架中。利用这些 ArMs,已经进行了许多新的自然反应的例子,其中一些已经表现出了很大的生物相容性。鉴于该领域的发展速度如此之快,本综述旨在强调一些重要的研究,这些研究已经开始在该领域迈出下一步;即开发以 ArM 为中心的药物疗法或生物技术工具。